entertainment -WSS

entertainment

author：comprehensive 2025-09-29 18:18:46 - browse：3

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Takeaways from AdvaMed, the largest medical devices conference

explore

WSS

Health AI: on the border between health care and tech

Humana CEO Bruce Broussard to step down in 2024

Judge sides with young activists in first

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Illumina slashes 2023 revenue projections yet again

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

knowledge

entertainment

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Hospitals are dialing back on venture capital investing

Dobbs anniversary: the lost opportunity of abortion as health care

Peter Marks talks Operation Warp Speed for Rare Diseases

Heart attack and stroke risk calculators need revising

Humana CEO Bruce Broussard to step down in 2024

Tori Bowie and the unacceptable rates of Black maternal death

Massive project maps cells in human brain in unprecedented detail

Medicare details structure of new drug price negotiation program

Bird flu researchers hone in on Finland’s mink farms

knowledge

Female surgeons have lower rates of long

Schizophrenia gene found to be linked to cells' energy dysfunction

Wellcome Trust names Røttingen as its new CEO

Mark Cuban is blaming the wrong people for high drug costs

Illinois Supreme Court finds assault weapons ban constitutional

Health AI: on the border between health care and tech

knowledge

explore

explore

hotspot